A bireporter recombinant SARS-CoV-2 Omicron BA.5 for in vitro and in vivo studies
Microbiology Spectrum · 2026
DOI: 10.1128/spectrum.00217-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Esteban M Castro und 12 weiteren Autor:innen. Beteiligte Einrichtung: Texas Biomedical Research Institute, San Antonio, Texas, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, Alpha-1 Foundation.
Abstract (Originalsprache)
The continuous emergence of variants of concern (VoCs) represents a significant challenge to effectively control severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although FDA-approved vaccines and antivirals have been successfully developed and implemented for the prophylactic and therapeutic intervention of SARS-CoV-2 infection, recent VoCs could escape protection garnered by previous vaccine and antiviral approaches. Determining the efficacy of prophylactics and/or therapeutics against recent VoCs will assist in efficiently controlling currently circulating SARS-CoV-2 strains. We used our previously described bacterial artificial chromosome-based reverse genetics approach for Omicron BA.5 to generate a recombinant SARS-CoV-2 BA.5 encoding a fusion of ZsGreen to Nanoluciferase (rBA.5 ZsG-Nluc) from the locus of the viral nucleocapsid (N) protein separated by the porcine teschovirus-1 2A proteolytic cleavage site. The rBA.5 ZsG-Nluc replicates to levels comparable to recombinant BA.5 wild type (rBA.5 WT) and expresses high levels of ZsG and Nluc in cultured cells. This facilitates tracking viral infection and the identification of antivirals and neutralizing antibodies with EC 50 and NT 50 values, respectively, similar to those obtained with rBA.5 WT. Importantly, in Keratin-18 human angiotensin-converting enzyme-2 mice, rBA.5 ZsG-Nluc retains the same pathogenicity and ability to replicate in the lungs of infected mice as rBA.5 WT. Using rBA.5 ZsG-Nluc, we detected Nluc activity systemically and Nluc and ZsG expression in the lungs of infected mice using an in vivo imaging system. Our results demonstrate the feasibility of using rBA.5 ZsG-Nluc to track viral infections and identify prophylactics and therapeutics against recent SARS-CoV-2 VoCs in vitro , ex vivo , and in vivo . IMPORTANCE Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative virus of the coronavirus disease 2019 pandemic, is continually evolving to escape immunity acquired by previous natural infections or vaccinations. Moreover, recent SARS-CoV-2 variants of concern (VoCs) have acquired antiviral-resistant mutations to FDA-approved drugs. The emergence of these VoCs highlights the importance of identifying new prophylactics and therapeutics against currently circulating SARS-CoV-2 strains. We generated a recombinant bireporter Omicron BA.5 SARS-CoV-2 (rBA.5 ZsG-Nluc) that expresses reporter proteins, which are useful for cellular and whole animal studies, and has similar viral replication and pathogenicity to a wild-type recombinant Omicron BA.5 SARS-CoV-2. In Keratin-18 human angiotensin-converting enzyme-2 mice, rBA.5 ZsG-Nluc infection can be tracked systemically or in the lungs of infected mice using an in vivo imaging system. We establish a proof-of-concept platform of rBA.5 ZsG-Nluc in combination with an ancestral SARS-CoV-2 strain expressing mCherry to simultaneously identify antivirals and neutralizing antibodies against original and recent SARS-CoV-2 strains.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Texas Biomedical Research Institute, San Antonio, Texas, USA.
- Graduate School of Biomedical Sciences, Long School of Medicine at University of Texas Health & Science Center, San Antonio, Texas, USA.
- Department of Microbiology, College of Agriculture and Life Sciences, Cornell University, Ithaca, New York, USA.
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
ORCID-Profile: Esteban M Castro, Chengjin Ye, James J Kobie, Adolfo García-Sastre, Hector C Aguilar, Luis Martinez-Sobrido
Förderung
- NIH HHS
- NIAID NIH HHS
- Alpha-1 Foundation
- NIGMS NIH HHS
- National Institutes of Health
Zitieren
APA
Castro, E. M., Barre, R. S., Ye, C., Imbiakha, B., Ezzatpour, S., Cupic, A., Walter, M. R., Kobie, J. J., K Plemper, R., García-Sastre, A., Elsayed, A. M., Aguilar, H. C., & Martinez-Sobrido, L. (2026). A bireporter recombinant SARS-CoV-2 Omicron BA.5 for in vitro and in vivo studies. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00217-26
Vancouver
Castro EM, Barre RS, Ye C, Imbiakha B, Ezzatpour S, Cupic A, et al. A bireporter recombinant SARS-CoV-2 Omicron BA.5 for in vitro and in vivo studies. Microbiology Spectrum. 2026. doi:10.1128/spectrum.00217-26
BibTeX
@article{Castro2026,
author = {Castro, Esteban M and Barre, Ramya S and Ye, Chengjin and Imbiakha, Brian and Ezzatpour, Shahrzad and Cupic, Anastasija and Walter, Mark R and Kobie, James J and K Plemper, Richard and García-Sastre, Adolfo and Elsayed, Ahmed M and Aguilar, Hector C and Martinez-Sobrido, Luis},
title = {A bireporter recombinant SARS-CoV-2 Omicron BA.5 for in vitro and in vivo studies},
journal = {Microbiology Spectrum},
year = {2026},
doi = {10.1128/spectrum.00217-26}
}
EUVIMED